×
About 44,836 results

ALLMedicine™ Immunosuppression Center

Research & Reviews  21,899 results

Polysaccharide mycophenolate-based nanoparticles for enhanced immunosuppression and tre...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914372
Theranostics Li Y, Lou Y et. al.

Mar 5th, 2021 - Immune-mediated inflammatory diseases (IMIDs) are characterized by immune dysregulation and severe inflammation caused by the aberrant and overactive host immunological response. Mycophenolic acid (MPA)-based immunosuppressive drugs are potential ...

Withdrawal of Combination Immunotherapy in Paediatric Inflammatory Bowel Disease - An I...
https://doi.org/10.1097/MPG.0000000000003098
Journal of Pediatric Gastroenterology and Nutrition; Meredith J, Henderson P et. al.

Mar 4th, 2021 - To assess current practices around the use of combination immunosuppression in paediatric inflammatory bowel disease (PIBD) with a focus on the subsequent withdrawal process. A web-based, 43 question survey. Surveys were completed by 70 paediatric...

Immunotherapy of Tumor RNA-Loaded Lipid Nanoparticles Against Hepatocellular Carcinoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920588
International Journal of Nanomedicine; Zhang Y, Xie F et. al.

Mar 4th, 2021 - Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Most current therapeutic strategies primarily include localized treatment, lacking effective systemic strategies. Meanwhile, recent studies have sugges...

EBV Positive Mucocutaneous Ulcer (EBVMCU): Single Center Series of Three Cases and Revi...
https://www.ncbi.nlm.nih.gov/pubmed/33653791
Annals of Clinical and Laboratory Science; Fei F, Reddy V et. al.

Mar 3rd, 2021 - EBV positive mucocutaneous ulcer (EBVMCU) is a newly recognized clinicopathologic entity in the 2017 World Health Organization (WHO) classification. Patients frequently present with an isolated ulcerative lesion in mucosal and cutaneous sites with...

Atezolizumab alleviates the immunosuppression induced by PD‑L1‑positive neutrophils and...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751480
Molecular Medicine Reports; Chen J, Chen R et. al.

Mar 3rd, 2021 - Atezolizumab can reduce immunosuppression caused by T lymphocyte apoptosis in various cancer types. The current study aimed to investigate whether this drug can also alleviate immunosuppression during sepsis. For that purpose, a C57BL/6 mouse seps...

see more →

Guidelines  29 results

Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in...
https://doi.org/10.1097/TP.0000000000003270 10.1097/tp.0000000000001129 10.1097/tp.0000000000001040 10.1111/trf.12064 10.1111/ajt.14752 10.1016/0197-2456(95)00134-4 10.1097/tp.0000000000001651 10.1111/j.1600-6143.2004.00360.x 10.1111/j.1600-6143.2012.04013.x 10.1155/2017/5201098 10.1097/tp.0b013e31827a19cc 10.1111/ajt.12589 10.1111/ajt.12590 10.1097/tp.0000000000000869 10.1038/nrneph.2012.81 10.1097/tp.0b013e3181a44206 10.1097/tp.0b013e3182139da1 10.1111/j.1600-6143.2012.04251.x 10.1097/tp.0b013e3182543950 10.1038/ki.2012.190 10.1097/tp.0b013e31827d62e3 10.1111/j.1600-6143.2012.04325.x 10.1111/ajt.12859 10.1097/01.tp.0000438196.30790.66 10.1097/tp.0000000000000216 10.1111/j.1600-6143.2008.02441.x 10.1016/j.humimm.2007.01.006 10.1681/asn.2016030368 10.1056/nejmoa1302506 10.1681/asn.2009101065 10.1111/j.1600-6143.2006.01721.x 10.1097/tp.0b013e3182777f28 10.1038/ki.2015.275 10.1097/tp.0000000000001487 10.1681/asn.2014040326 10.1111/j.1399-3046.2011.01599.x 10.1097/tp.0b013e318203fd26 10.1097/tp.0b013e3181ac6198 10.1111/j.1432-2277.2008.00755.x 10.1111/j.1600-6143.2009.02800.x 10.1111/ajt.13010 10.1016/j.trre.2016.02.002 10.1681/asn.2012070664 10.1111/ajt.13295 10.1016/j.humimm.2016.05.025 10.1681/asn.2014080837 10.1097/tp.0b013e31822872dd 10.1097/01.tp.0000441091.47464.c6 10.1681/asn.2014111120 10.1016/j.healun.2010.08.020 10.1111/ajt.13700 10.1007/s00467-016-3322-8 10.1097/tp.0b013e3182888db6 10.1681/asn.2013101144 10.1097/tp.0000000000000315 10.1111/ajt.12287 10.1111/ajt.12462 10.1016/j.inmuno.2013.10.003 10.1097/01.tp.0000441362.11232.48 10.1111/tri.12648 10.1016/j.trim.2013.07.002 10.1371/journal.pmed.1002572 10.1111/j.1600-6143.2011.03961.x 10.5301/jn.5000207 10.1111/ajt.12365 10.1681/asn.2014040399 10.1111/j.1600-6143.2009.02764.x 10.1111/j.1600-6143.2011.03840.x 10.1111/ajt.13132 10.1111/ajt.13795 10.1111/ajt.13803 10.1093/ndt/gfq096 10.1111/tri.12798 10.1038/ki.2013.465 10.1038/ki.2013.484 10.1111/j.1600-6143.2006.01360.x 10.1136/bmj.38569.471007.ae 10.1016/j.trre.2015.01.002 10.3109/03602532.2016.1151037 10.1186/2047-1440-3-7 10.1097/tp.0b013e3182292426 10.1152/jappl.1989.66.3.1397 10.1097/txd.0000000000000536 10.1136/bmj.h3163 10.1097/tp.0000000000000384 10.1097/ftd.0b013e3182708edf 10.1016/j.clinthera.2014.02.021 10.1111/ajt.14504 10.1097/tp.0b013e318199c1c7 10.1111/ajt.14109 10.1097/txd.0000000000000710 10.1681/asn.2017030287 10.1111/j.1600-6143.2009.02726.x 10.1097/01.tp.0000110408.83054.88 10.1111/j.1600-6143.2008.02495.x 10.1097/md.0000000000002196 10.7182/prtr.21.4.f044g7v3r803838t 10.1097/tp.0b013e3182725532 10.1371/journal.pone.0165233 10.1016/j.transproceed.2015.11.027 10.1016/j.transproceed.2014.07.011 10.1093/ndt/gfr374 10.1016/j.trim.2008.08.005 10.1097/tp.0000000000000958 10.1111/ajt.12493 10.1002/14651858.cd004759.pub2 10.1097/tp.0000000000000064 10.1111/j.1600-6143.2009.02968.x 10.1097/tp.0000000000000592 10.1111/ajt.13871 10.1111/ajt.13663 10.1111/ajt.14228 10.1097/tp.0b013e31825d1587 10.1097/tp.0000000000002049 10.1111/j.1600-6143.2006.01613.x 10.1097/00007890-198305000-00006 10.1097/00007890-198108000-00019 10.1111/j.1600-6143.2009.02591.x 10.1016/j.transproceed.2015.01.030 10.1111/j.1399-0012.2008.00902.x 10.1111/ajt.14520 10.1681/asn.2017070818 10.1111/ajt.14001
Transplantation Crespo M, Zárraga S et. al.

Jul 13th, 2020 - Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper.|2020|Crespo M,Zárraga S,Alonso Á,Beneyto I,Díaz Corte C,|blood,diagnosis,immunology,prevention & ...

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: P...
https://doi.org/10.1016/j.ejca.2020.01.007
European Journal of Cancer (Oxford, England : 1990); Stratigos AJ, Garbe C et. al.

Mar 2nd, 2020 - Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated in cSCC etiopathogenesis include ultraviolet radiation exposure and ...

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
http://hugin.info/152918/R/2233733/878824.pdf

Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the firs...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASC...
https://doi.org/10.1200/JCO.18.00374
Journal of Clinical Oncology : Official Journal of the Am... Taplitz RA, Kennedy EB et. al.

Sep 4th, 2018 - To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment. ASCO and IDSA convened an update Expert Panel...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
http://ascopubs.org/doi/full/10.1200/JCO.18.00374
Taplitz,R.,et al

Sep 3rd, 2018 - Antibacterial and antifungal prophylaxis is recommended for patients who are at high risk of infection, including patients who are expected to have profound, protracted neutropenia, which is defined as < 100 neutrophils/µL for > 7 days or other ri...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  22,317 results

Polysaccharide mycophenolate-based nanoparticles for enhanced immunosuppression and tre...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914372
Theranostics Li Y, Lou Y et. al.

Mar 5th, 2021 - Immune-mediated inflammatory diseases (IMIDs) are characterized by immune dysregulation and severe inflammation caused by the aberrant and overactive host immunological response. Mycophenolic acid (MPA)-based immunosuppressive drugs are potential ...

Withdrawal of Combination Immunotherapy in Paediatric Inflammatory Bowel Disease - An I...
https://doi.org/10.1097/MPG.0000000000003098
Journal of Pediatric Gastroenterology and Nutrition; Meredith J, Henderson P et. al.

Mar 4th, 2021 - To assess current practices around the use of combination immunosuppression in paediatric inflammatory bowel disease (PIBD) with a focus on the subsequent withdrawal process. A web-based, 43 question survey. Surveys were completed by 70 paediatric...

Immunotherapy of Tumor RNA-Loaded Lipid Nanoparticles Against Hepatocellular Carcinoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920588
International Journal of Nanomedicine; Zhang Y, Xie F et. al.

Mar 4th, 2021 - Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Most current therapeutic strategies primarily include localized treatment, lacking effective systemic strategies. Meanwhile, recent studies have sugges...

EBV Positive Mucocutaneous Ulcer (EBVMCU): Single Center Series of Three Cases and Revi...
https://www.ncbi.nlm.nih.gov/pubmed/33653791
Annals of Clinical and Laboratory Science; Fei F, Reddy V et. al.

Mar 3rd, 2021 - EBV positive mucocutaneous ulcer (EBVMCU) is a newly recognized clinicopathologic entity in the 2017 World Health Organization (WHO) classification. Patients frequently present with an isolated ulcerative lesion in mucosal and cutaneous sites with...

Atezolizumab alleviates the immunosuppression induced by PD‑L1‑positive neutrophils and...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751480
Molecular Medicine Reports; Chen J, Chen R et. al.

Mar 3rd, 2021 - Atezolizumab can reduce immunosuppression caused by T lymphocyte apoptosis in various cancer types. The current study aimed to investigate whether this drug can also alleviate immunosuppression during sepsis. For that purpose, a C57BL/6 mouse seps...

see more →

News  589 results

Stem Cell Transplant Shows Long-term Benefit in MS
https://www.medscape.com/viewarticle/944656

Jan 24th, 2021 - The benefits of autologous hematopoietic stem cell transplant (AHSCT) for patients with multiple sclerosis (MS) persist for more than 10 years in the majority of patents, new data show. The study reports on 210 Italian patients who underwent AHSCT...

Dexamethasone May Curb Efficacy of Immune Checkpoint Blockade in Glioblastoma
https://www.medscape.com/viewarticle/941951

Dec 3rd, 2020 - NEW YORK (Reuters Health) - Dexamethasone given to combat cerebral edema in patients with glioblastoma may negatively affect immunotherapy, according to work in mice and clinical data. "There are many biologic, endogenous factors contributing to i...

NICE Recommends Innovative Treatment for Severe Blood Disorder for NHS Use
https://www.medscape.com/viewarticle/941022

Nov 15th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

Pandemic Drives Adaptations to Management Guidelines for Acute Colitis in Kids
https://www.medscape.com/viewarticle/937260

Sep 13th, 2020 - NEW YORK (Reuters Health) - The management of pediatric acute severe colitis (ASC) might need to be altered in the context of the COVID-19 pandemic, according to a RAND appropriateness panel. The European Crohn's and Colitis Organization/European ...

Fast Five Quiz: Relapsing-Remitting Multiple Sclerosis Management
https://reference.medscape.com/viewarticle/936615_5

Sep 3rd, 2020 - Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection of the brain that can lead to severe disability or death. Natalizumab has been associated with PML. Risk factors for PML are previous immunosuppression, duration of exp...

see more →